Peptides / Retatrutide
Retatrutide
(LY3437943)T2glp1literature
Biomarker Effects
No biomarker data available yet.
Dosing & Pharmacokinetics
Typical Dose2 mg
Frequencydaily
Routeclinician-directed
Half-Life6.0 days
Safety & Evidence
Retatrutide is a triple agonist GLP-1/GIP/glucagon receptor agonist in late-stage clinical trials (phase 3 as of 2024). Shows significant weight loss in trials.
Sources
Track Retatrutide precisely in the Vivy app.
Your precision instrument awaits.
Download Vivy